Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5655 USD | -6.16% | -17.38% | +10.28% |
Financials (USD)
Sales 2024 * | 98.05M | Sales 2025 * | 83.06M | Capitalization | 68.1M |
---|---|---|---|---|---|
Net income 2024 * | -94M | Net income 2025 * | -48M | EV / Sales 2024 * | 0.21 x |
Net cash position 2024 * | 47.51M | Net cash position 2025 * | 57.37M | EV / Sales 2025 * | 0.13 x |
P/E ratio 2024 * |
-0.71
x | P/E ratio 2025 * |
-1.63
x | Employees | 225 |
Yield 2024 * |
354% | Yield 2025 * |
354% | Free-Float | 97.23% |
Latest transcript on Atara Biotherapeutics, Inc.
1 day | -6.16% | ||
1 week | -17.38% | ||
Current month | -18.04% | ||
1 month | -25.20% | ||
3 months | -31.53% | ||
6 months | -53.26% | ||
Current year | +10.28% |
Managers | Title | Age | Since |
---|---|---|---|
Pascal Touchon
CEO | Chief Executive Officer | 61 | 19-06-23 |
Eric Hyllengren
DFI | Director of Finance/CFO | - | 17-12-31 |
Anhco Nguyen
CTO | Chief Tech/Sci/R&D Officer | 51 | 21-05-09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Carol Gallagher
CHM | Chairman | 59 | 12-12-31 |
Eric Dobmeier
BRD | Director/Board Member | 55 | 15-03-25 |
William Heiden
BRD | Director/Board Member | 64 | 15-11-22 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.03% | 0 M€ | 0.00% | - | |
0.03% | 0 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 0.5655 | -6.16% | 1,441,811 |
24-05-07 | 0.6026 | -4.32% | 1,664,665 |
24-05-06 | 0.6298 | -6.00% | 1,145,126 |
24-05-03 | 0.67 | +3.03% | 741,816 |
24-05-02 | 0.6503 | -5.00% | 2,214,549 |
Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.28% | 72.56M | |
+2.93% | 106B | |
+7.02% | 23.47B | |
-14.60% | 21.9B | |
-7.05% | 18.77B | |
-38.55% | 17.85B | |
-8.83% | 16.78B | |
+5.51% | 14.41B | |
+37.49% | 12.86B | |
+329.39% | 8.78B |
- Stock Market
- Equities
- ATRA Stock